In a report published Tuesday, Bank of America analyst Derik de Bruin downgraded the rating on Genomic Health GHDX from Buy to Neutral, and lowered the price target from $43.00 to $36.00.
In the report, Bank of America noted, “We are impressed by Genomic Health's scientific and commercial expertise as well as its execution to expand its tests' indications, launching new products, and broadening its geographic footprint. However, industry dynamics are also becoming increasingly more difficult due to competition, reimbursement, and regulatory pressures. As a result, we think that share appreciation may be limited over the next 12 months.”
Genomic Health closed on Monday at $32.97.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in